Brazil UDI Labeling and SIUD Transmission Timelines Explained

1. Key takeaways

Brazil’s UDI deadlines exist in only one set, from the body of Article 15 of RDC 591/2021, items I–IV (current text as amended by RDC nº 884/2024): Class IV 3.5 years, Class III 4 years, Class II 5 years, Class I 6 years; the Class I figure is the original value, and 884/2024 extended only Classes IV, III and II by 1 year each. The real difference lies in the starting points. Labeling and marking run from the effective date of the resolution itself, 2022-01-10; SIUD data transmission runs, under Article 15, §3, from the moment ANVISA publishes by normative instruction that its database can receive UDI information — that instruction is IN nº 426/2026, effective 2026-03-01. In the words of ANVISA’s official UDI page, SIUD has been operational since that effective date. GRZAN’s judgment: the most common error is treating the labeling deadline as the data deadline, leaving labels compliant while the database stays empty. [Calendar dates derived from Article 15 and the starting points, consistent with the official deadline infographic; a practical estimate.]

2. Legal basis

• UDI requirements — RDC nº 591/2021, resolution of December 21, 2021, effective January 10, 2022 (Article 19), Article 15 and §1, §2, §3 (SIUD database transmission), §4 (UDI transmission in vigilance notifications), Article 16 single paragraph, Article 18 (repeals RDC nº 232/2018); Article 15 amended by RDC nº 884/2024, not the original text
• Amendment of UDI class deadlines — RDC nº 884/2024, resolution of June 26, 2024 (the Ementa uses the word Altera: an amending act, not a replacing act), amending the class deadlines of Article 15, items I–IV of RDC 591/2021: Classes IV, III and II extended by 1 year each, Class I unchanged at 6 years; its Article 3 also repeals Article 8, §1 of RDC 591/2021
• Transmission and management of the UDI database SIUD — IN nº 426/2026, issued February 13, 2026 and published in the DOU on February 18, 2026, Articles 3, 11, 13 and 16
• ANVISA official UDI page — gov.br/anvisa/pt-br/assuntos/produtosparasaude/udi, stating that SIUD has been operational since the effective date of IN nº 426/2026 (March 1, 2026) (page wording; the official news announcement of March 2, 2026 is a press-release date, not a date reference)

3. Expert insights

These two sets of deadlines correspond to two independent obligations that cannot substitute for each other. The first governs whether compliant UDI is printed on the physical product; its starting point, under the body of Article 15, is the resolution’s effective date, so Class IV 2025-07-10, Class III 2026-01-10, Class II 2027-01-10 and Class I 2028-01-10. The second set governs whether data enters the database; its starting point is given separately by Article 15, §3 — from the moment ANVISA publishes by normative instruction that its UDI database can receive the information listed in Annex I — so Class IV 2029-09-01, Class III 2030-03-01, Class II 2031-03-01 and Class I 2032-03-01; Article 11 of IN 426/2026 ties the mandatory transmission duty to this class schedule. GRZAN recommends drawing both timelines on one chart with the starting points marked in different colors — finishing one does not mean the other is done.

Another clause easily overlooked is Article 13 of IN 426/2026 — the basis on which ANVISA suspends data transmission for a class of devices. [Paragraph content is a practical estimate; DOU issue 32 is the verification entry point.] The channel is not unconditionally open, so reserve a contingency plan.

The second key point: §3 and §4 are two independent trigger lines and must not be merged. §3 is the SIUD database transmission described above. §4 separately covers the duty to transmit UDI information in adverse event, technical complaint and field action notifications, triggered when ANVISA publishes that the electronic system receiving notifications is ready — neither the same system nor the same date as SIUD. GRZAN warns: §4 is an independent obligation almost never mentioned in secondary sources; the UDI duty on the vigilance chain cannot be deferred just because the SIUD deadline has not arrived.

The third insight is the additional buffer in Article 15, §1, whose scope must be stated precisely: only for reusable devices with the UDI carrier applied directly to the device body is the applicable class deadline extended by a further 2 years, giving Class IV 2027-07-10, Class III 2028-01-10, Class II 2029-01-10 and Class I 2030-01-10. GRZAN warns against generalizing this into permanent direct marking for all products — different concepts — and it does not reach the SIUD transmission deadlines.

The fourth insight is the traceability labels for implantable products, where a widely circulated figure must be corrected. Under Article 15, §2, traceability labels for coronary stents, drug-eluting coronary stents and hip and knee joint replacement implants must carry the UDI carrier, mandatory from the effective date of the resolution; Article 16, single paragraph limits the product scope to products manufactured after June 20, 2020. The claim that this became mandatory from 2020-06-25 under RDC 232/2018 is wrong — RDC 232/2018 was expressly repealed by Article 18; its 25 de junho is the 2018 DOU publication date misread as the 2020 effective date.

The fifth insight is the possible inversion of order. Article 3 of IN 426/2026 requires UDI data transmission to be completed before the device is placed on the Brazilian market, meaning that for some companies data compliance will become the binding constraint before the labeling deadline. GRZAN’s judgment: Class IV products in particular should back-plan their market entry from the data deadline.

A related point is the classification basis. Article 5 of RDC 751/2022 divides devices into Classes I, II, III and IV, and the UDI deadlines follow the classification entirely; once the classification is contested, the deadlines hang in the air. Archive the classification conclusion together with the classification rules.

Another related point is post-market changes: changes to model, packaging level or label content may trigger a new UDI-DI and a new transmission. Manage these in parallel with the three-tier change classification of Article 16 of RDC 751/2022, so the same change does not reach different conclusions on two processes.

4. Practical recommendations

• Build a dual-track timetable: one track for label carriage, one for SIUD transmission, each with its starting point marked.
• Back-plan by risk class with Class IV first; start by confirming the labeling status and disposition plan for existing Class IV products.
• For reusable devices with UDI applied to the body, plan the 2-year extension as a separate line item.
• Re-verify the deadline table against the DOU, AnvisaLegis and the official UDI page every six months.
• Watch the suspension cases of Article 13 of IN 426/2026 and prepare a contingency for a device class being suspended.
• Track UDI transmission on the vigilance chain (Article 15, §4) separately; do not mix it into the SIUD schedule.
• Bring data transmission and label revisions into one change management process, managed in parallel with the classification of Article 16 of RDC 751/2022.

5. Verification checklist

• □ Verify the Brazilian risk class of the product (Article 5 of RDC 751/2022)
• □ Verify the current labeling and marking deadline for the class (body of Article 15, from the resolution effective date 2022-01-10)
• □ Verify the SIUD transmission deadline (Article 15, §3, 3.5/4/5/6 years from the IN 426/2026 effective date 2026-03-01)
• □ Verify SIUD system availability and any suspension notices under Article 13
• □ Verify that the vigilance UDI transmission duty of Article 15, §4 is tracked separately (trigger: readiness announcement of the electronic system)
• □ Verify whether the device is reusable with the UDI carrier applied to the body — only then does the 2-year extension of Article 15, §1 apply
• □ Verify the traceability label duty for coronary stents, drug-eluting coronary stents and hip/knee replacement implants (Article 15, §2 and Article 16, single paragraph)
• □ Verify that citations state as amended by RDC nº 884/2024 (an amending act, not a replacing act) and do not describe Class I as extended
• □ Verify that the classification conclusion is supported by classification rules
• □ Verify whether packaging level or model changes trigger a new UDI-DI
• □ Verify the current text of Article 15 of RDC 591/2021 (including the RDC nº 884/2024 amendment) and the database readiness announcement of Article 15, §3 against the DOU

Regulatory information verified as of October 29, 2026

GRZAN Regulatory Team

GRZAN turns Brazil’s UDI timelines into executable project plans: dual-track schedules for labeling and SIUD transmission, UDI-DI assignment and change management, data transmission validation against IN 426/2026, and vigilance-chain UDI obligations under RDC 591/2021. For UDI and SIUD implementation support in the Brazilian market, contact info@grzanglobal.com.